Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer
Hon Yan Kelvin Yip(Stella Therapeutics (United States)), Antonella Papa(Discovery Institute)
Cited by 17
Related Papers
The PTEN–PI3K Axis in Cancer
|Biomolecules|2019|292